All Stories

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline.

Mar 5, 2025 - 14:27
 0
Jazz hands over $935M to buy Chimerix for near-approval cancer drug
Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO voiced an interest in diversifying the pipeline.
Read More

Tags:

Previous Article

iDealwine hails strong year as it anticipates 2025 opening of New York office

Next Article

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab,...

Related Posts

Former NIH director Francis Collins retires, calls agency the 'main piston' in biomedical discovery

Former NIH director Francis Collins retires, calls agen...

Mar 5, 2025  0

Resmed debuts wearable, at-home sleep apnea test

Resmed debuts wearable, at-home sleep apnea test

Apr 4, 2025  0

J&J’s Monarch bronchoscopy robot cleared by FDA to connect to live CT scans

J&J’s Monarch bronchoscopy robot cleared by FDA to conn...

Mar 12, 2025  0